The National Academies of Sciences, Engineering and Medicine (NASEM) released A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report in March 2017. How do these strategies apply to the work of cancer control professionals, viral hepatitis community partners, and policy makers? What can you do to reduce new cases of liver cancer in your community?
This CDC-funded webinar will be accompanied by slides, notes and resources suitable to present to your comprehensive cancer control program staff, coalition members and stakeholders.
- Describe the work of the Center for Disease Control and Prevention's Division of Viral Hepatitis and Division of Cancer Prevention and Control
- Relay strategies and key interventions to eliminate new viral hepatitis B and C infections and reduce the risk of liver cancer to others
- Describe the connection between chronic hepatitis B and C viruses and liver cancer and at-risk populations
- List key interventions outlined in the NASEM report to eliminate new viral hepatitis B and C infections and reduce the risk of liver cancer
- Locate technical assistance resources and partner organizations to introduce or improve strategies to eliminate hepatitis B and C viruses and reduce liver cancer
Behnoosh Momin, DrPH, MS, MPH is a health scientist in the Division of Cancer Prevention and Control's Comprehensive Cancer Control Branch, Scientific Support and Clinical Translation Team. She currently provides scientific expertise to a wide range of the Division's research studies, including project lead on a large American Recovery and Reinvestment Act-funded research study that involves a mixed-methods approach to identify promotional and cessation interventions for tobacco control in decreasing cancer rates. She is also a co-lead on a study measuring the effects of state and local radon policies. Dr. Momin is the co-founder of CDC's Tobacco-Related Cancers workgroup, which promotes tobacco-related cancer epidemiological research, education, and awareness to decrease cancer incidence, morbidity, and mortality.
Blythe Ryerson, PhD, MPH is the Associate Director of Science for the Division of Viral Hepatitis (DVH) at CDC. She is responsible for assisting the Division Director in shaping and implementing the scientific vision and mission of viral hepatitis research and public health programs at CDC. Dr. Ryerson received her doctorate in epidemiology from Emory University in Atlanta, GA. She joined CDC as a cancer epidemiologist in 2001, spending most of her tenure conducting cancer epidemiology and surveillance research, including examining the association of hepatocellular carcinoma and viral hepatitis. She joined the Division of Viral Hepatitis earlier this year.
Aubrey Van Kirk Villalobos, MPH, MEd is Director of Cancer Control and Health Equity and the Institute for Patient-Centered Initiatives and Health Equity at the George Washington University Cancer Center in Washington, DC and a doctor of public health student in health behavior. She leads GW's CDC-funded Comprehensive Cancer Control technical assistance for programs and coalitions across the country. Aubrey also oversees several research and outreach projects focused on reducing health inequities, particularly among the local LGBTQ community. Prior to joining the GW Cancer Center, she worked in the International Outreach Program at St. Jude Children's Research Hospital in Memphis, TN, where she helped to develop, implement, and evaluate a school-based cancer prevention curriculum for elementary, middle, and high school students.